Meningitis Diagnostic Testing Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The global meningitis diagnostic testing market size was valued at USD 119.5 million in 2023 and is expected to exhibit growth at a CAGR of 3.5% from 2024 to 2034. The expansion of the market appears to be dependent on many market drivers such as the increase in occurrence of meningitis cases or global promotions and development of new technologies as well as new treatment options.
For instance, the National Centre for Biotechnology Information (NCBI) estimates that meningitis caused 236,222 deaths and loss of 15,649,865 Years of Life (YLL) globally in 2019. Such a figure is alarming and underscores the necessity for valid measures to be adopted and to control the situation under consideration.
The increased demand for early and precise diagnosis has further caused demand for new improvements in diagnostic testing methods such as the polymerase chain reaction (PCR) assay and the next-generation sequencing (NGS). Furthermore, such drugs as antibiotics, corticosteroids, and vaccines under design to improve outcomes in patients with such meningitis are driving up the demand in this marketplace. Health promotions and educational programs facilitating the improvement of the current situation with meningitis diagnosis and treatment also contribute substantially to the growth of the market. Thus, these reasons together with active studies aimed at inventing vaccines and more accurate diagnostic tests fuel the growth of the meningitis diagnostic testing market.
Meningitis diagnostic testing refers to a range of laboratory tests and procedures that are utilized to measure the presence of meningitis, which is in essence an inflammation of the membranous covering of the brain and spinal cord. The tests seek to ascertain the different forms of meningitis that are to be either bacterial or viral or fungal or even parasitic, and alternatively infections from autoimmune disorders.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Meningitis Diagnostic Testing Market size in 2023: | USD 119.5 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2023 - 2032 CAGR: | 3.5 |
2023 Value Projection: | USD 161.9 Million |
Historical Data for: | 2021 – 2023 |
No of Pages: | 140 |
Tables, Charts & Figures: | 150 |
Segments Covered: | Test Type, Age Group, End Use, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
A key factor facilitating the growth of the market is the increase in technological advancements in molecular diagnostics. These inventions constitute improvements in the speed, accuracy, and sensitivity of diagnostic processes.
Based on test type, the market is segmented into latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and other test types. The PCR assay segment dominated the market with USD 42.2 million in 2023.
Based on age group, the meningitis diagnostic testing market is divided into infants, children, adolescents, young adults, and adults. The infants segment accounted for significant market share of 39.4% in 2023.
Based on end use, the meningitis diagnostic testing market is divided into hospitals, diagnostic centers, and other end users. The hospitals segment dominated the market with USD 72.8 million in 2023.
North America meningitis diagnostic testing market is expected to grow at 3.3% CAGR, to reach USD 73.7 million by the end of 2032.
The UK meningitis diagnostic testing market is experiencing robust growth in Europe market.
The Asia Pacific meningitis diagnostic testing market is witnessing substantial growth of 3.8% during the analysis period.
The market is extremely competitive and has constant technology advancement and innovation. A major part of the market is held by renowned top drug manufacturers due to their wide range of advanced diagnostic tools and techniques and treatment drugs. Also, mergers, acquisitions, and collaborations are among the strategic activities that consolidate the position of key players in the market and provide them with the ability to broaden the range of products in the existing and new markets.
Prominent players operating in the meningitis diagnostic testing industry include:
Market, By Test Type
Market, By Age Group
Market, By End Use
The above information is provided for the following regions and countries:
The leading companies in the industry include Abbott Laboratories, Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories, Certest Biotec, ELITechGroup, F. Hoffmann-La Roche, IMMY, Seegene, Siemens Healthineers, Thermo Fisher Scientific, and Uniogen.
The North America market is expected to grow at a 3.3% CAGR, reaching USD 73.7 million by 2032, led by advanced healthcare infrastructure and rising awareness about meningitis.
The PCR assay segment dominated the market with USD 42.2 million in 2023 due to its superior accuracy, sensitivity, and speed in detecting genetic material of pathogens directly from cerebrospinal fluid samples.
The market size of meningitis diagnostic testing reached USD 119.5 million in 2023 and is set to grow at a 3.5% CAGR from 2024 to 2032, driven by the increasing global prevalence of meningitis cases.